

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2020/180356 A9

(43) International Publication Date
10 September 2020 (10.09.2020)

WIPO | PCT

(51) International Patent Classification:

A61K 31/5685 (2006.01) A61P 9/00 (2006.01)
A61K 45/06 (2006.01) A61P 9/04 (2006.01)

Milano (IT). **BARRASSI, Paolo**; Via Campagnetta 6/B,
21010 Castelveccana (VA) (IT).

(21) International Application Number:

PCT/US2019/060961

(74) Agent: **REED, Janet E.** et al.; Potter Anderson and Cor-
roon LLP, 1313 N. Market Street, Wilmington, Delaware
19801 (US).

(22) International Filing Date:

12 November 2019 (12.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/814,149 05 March 2019 (05.03.2019) US

(71) Applicant: **WINDTREE THERAPEUTICS, INC.**
[US/US]; 2600 Kelly Road, Warrington, Pennsylvania
18976 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(72) Inventors: **BIANCHI, Giuseppe**; Piazza Adigrat 4, 20133
Milano (IT). **FERRARI, Patrizia**; Gasparotto 57A, 21100
Varese (IT). **FERRANDI, Mara**; Via Cenisio 34, 20100

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF)




FIG. 1

(57) Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

12 November 2020 (12.11.2020)

(15) Information about Correction:

see Notice of 12 November 2020 (12.11.2020)